Clinical trials: Fasting Glucose
- Condition Fasting Glucose
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Fast-acting insulin aspart (faster aspart) will be tested to see how well it works and if it is safe. The study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine…
- Trial name
- NCT04588259
- Testing
- Faster aspart, Insulin aspart, Insulin degludec
- Where
- 40 sites in China, Hong Kong
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Bone Metabolism
Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.
The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.
- Trial name
- NCT00708175
- Testing
- Pioglitazone
- Where
- 34 sites in United States
- Volunteers
- 156 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes
The study is done to compare how faster aspart is taken up, broken down and removed from the body between different age groups (children [6-11 years], adolescents [12-17 years] and adults [18-64 years]) who have diabetes.
- Trial name
- NCT03407599
- Testing
- Faster aspart, Insulin aspart (NovoRapid®)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Effect of Fiasp® in Type 1 Diabetes Treatment
Fiasp® is a meal-time insulin that has been available in Sweden since June 2017. This study will investigate the effectiveness of Fiasp® in treating Type 1 Diabetes Mellitus.
- Trial name
- NCT03895515
- Testing
- Fiasp®
- Where
- Sweden
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S